Biogen search focuses on scientists; Medicare Advantage ratings fall

The selection of a researcher would be a major departure for Biogen, which has tended to hire corporate operators to serve as CEO. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by       STAT+: Biogen CEO search focuses on scientists, with former J&J exec as a leading candidate By Matthew Herper and Adam Feuerstein and Damian Garde Venrock Mathai Mammen, who until recently was the head of R&D at pharmaceutical giant Johnson & Johnson, would be a departure for Biogen. Read More STAT+: Medicare Advantage quality ratings plunge as government resets to pre-pandemic standards By Bob Herman Adobe The lower quality ratings will drain billions of dollars in bonuses that flow to health insurers that get high marks for the plans. Read More STAT+: Merck's Covid-19 pill was no better than placebo in lowering the risk of hospitalization By Ed Silverman Merck The study failed to reach an outcome that was used last year by regulators – such as those in the U.S. and U.K. — to authorize the medicine. Read More Sponsor content by NOVAVAX How is Novavax helping to provide enhanced immunity with its vaccine technology? Novavax uses a naturally derived saponin ingredient in its vaccine technology. This proprietary adjuvant was developed with the goal of stimulating an enhanced immune response. Learn more. STAT+: Drugmakers will be penalized if they hike prices on patients in private insurance market By Rachel Cohrs Adobe A Medicare official said Thursday that drug price hikes on privately insured patients will be considered in assessing penalties on drugmakers. Read More STAT+: FDA and Covis release dueling documents over the fate of a controversial drug for premature births By Ed Silverman Adobe Keeping Makena available would "unnecessarily expose patients to the risks associated with a drug that is not shown to be effective," FDA says Read More Opinion: FDA's plan to define 'healthy' for food packaging: Better than the existing labeling anarchy, but do we really need it? By Marion Nestle Adobe The FDA has proposed rules for letting manufacturers claim that a food product is "healthy." It's a good step, but do we need such a label? Read More STAT+: Health plans say texting could help reach underserved patients. But a federal rule is getting in their way By Mohana Ravindranath Adobe Health plans trying to reach low-income and underserved customers say they’re being stymied by a decades-old federal rule limiting texting. Read More Friday, October 7, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser